H.C. Wainwright analyst Ed Arce maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $25.00.
Ed Arce’s Buy rating for Vera Therapeutics is influenced by a confluence of promising clinical data and a robust valuation model. The company’s lead candidate, atacicept, has shown compelling 72-week data from its ORIGIN trial for treating IgA nephropathy (IgAN), which includes stable kidney function and significant reductions in disease markers. This data is considered an early indicator of potential success in the upcoming pivotal ORIGIN 3 trial. The stability of the estimated glomerular filtration rate (eGFR) and reductions in proteinuria observed in the trial are particularly encouraging, as they suggest a potential for disease modification. Arce’s confidence is further bolstered by atacicept’s consistent safety profile across different studies.
Furthermore, the valuation model employed by Ed Arce incorporates a risk-adjusted net present value (rNPV) approach, leading to a price target of $25. This takes into account projected revenues from atacicept’s use in both IgAN and lupus nephritis (LN), alongside another candidate, MAU868, for BK virus nephropathy. The model reflects an optimistic yet cautious estimation of the therapies’ market penetration and peak sales, while acknowledging the inherent risks associated with clinical development and regulatory approvals. Arce’s recommendation also factors in the current market conditions and recognizes the potential hurdles that could affect the investment thesis, such as clinical trial setbacks, regulatory challenges, and intellectual property disputes.
According to TipRanks, Arce is a 4-star analyst with an average return of 6.6% and a 42.69% success rate. Arce covers the Healthcare sector, focusing on stocks such as Talphera, CymaBay Therapeutics, and Mirum Pharmaceuticals.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $26.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vera Therapeutics (VERA) Company Description:
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Read More on VERA:
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
- 3 Best Stocks to Buy Now, 1/25/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 1/23/2024, According to Top Analysts
- Vera Therapeutics price target raised to $25 from $22 at JPMorgan
- Vera Therapeutics to host research and development day
